Tag: EFX

  • This Could be a Game-Changer for NASH Patients

    This Could be a Game-Changer for NASH Patients

    Shares of small-cap, Akero Therapeutics (AKRO) are up more than 115%, or $14.17. Volume is up to 34.18 million, as compared to daily average volume of 406,516, as well. All after the company posted positive phase 2b trial data for its experimental nonalcoholic steatohepatitis (NASH) candidate known as efruxifermin (EFX). “The statistically significant histological improvements…